SynAct Pharma AB ("SynAct") today announced that the European Patent Office (EPO) issued an “Intention to grant” for SynAct’s patent application covering the company’s leading drug candidate AP1189 in methods of treating kidney diseases.

SynAct Pharma AB ('SynAct') hereby announces that the company has filed a patent application to the European Patent Office (EPO) covering the use of AP1189 for the treatment of COVID-19 infection,

12.50 – 13.20. Read more SynAct Pharma AB, c/o Medicon Village AB, Scheelevägen 2,SE-223 81 Lund, Sweden. Telephone +45 28 44 75 67. E-post joo@synactpharma.com.Company registration number: 559058-4826. SynAct Pharma AB (publ) (”SynAct” or ”the Company”) has, in accordance with the announcement made in a press release yesterday, successfully completed a directed share issue of 1,600,000 shares at a price of SEK 50 per share (the “Directed Share Issue”).

In total, the Board of Directors and management have agreed on a subscription of approximately SEK 1.2 million of TO 2 ahead of the exercise period that will run 2020-11-09 SynAct Pharma AB ("SynAct") today announced that the European Patent Office (EPO) issued an "Intention to grant" for SynAct's patent application covering the company's leading drug candidate AP1189 in methods of treating kidney diseases.. SynAct has received information that the company obtained an "Intention to grant" from the EPO regarding their patent application 19734023.5 (EP … SynAct Pharma AB ("SynAct" eller "Bolaget") meddelar härmed att Bolagets aktieägare TJ Biotech ApS (helägt av styrelseledamoten tillika CSO Thomas Jonassen) och Quantass ApS (ägt av verkställande direktören Jeppe Øvlesen och dennes hustru Ghita Øvlesen) har genomfört en bolagsrättslig omstrukturering varigenom respektive bolags innehav av aktier i SynAct har övergått genom fusion Synact Pharma Press release 20201109. Markets Insider and Business Insider Editorial Teams were not involved in the creation of this post. SEE ALSO: SynAct Pharma is a pharmaceutical group that conducts research and development in the treatment of inflammatory diseases. The company has developed a platform technology that is aimed at severe conditions in chronic inflammatory diseases, and foremost joint injuries.

SynAct Pharma AB ("SynAct" eller "Bolaget") meddelar härmed att Bolagets aktieägare TJ Biotech ApS (helägt av styrelseledamoten tillika CSO Thomas Jonassen) och Quantass ApS (ägt av verkställande direktören Jeppe Øvlesen och dennes hustru Ghita Øvlesen) har genomfört en bolagsrättslig omstrukturering varigenom respektive bolags innehav av aktier i SynAct har övergått genom fusion

A or 1, Open First attachment. SynAct Pharma is a pharmaceutical group that conducts research and development in the treatment Swedish version of press release published earlier today. 23 sep.

SynAct Pharma är en läkemedelskoncern som bedriver forskning och utveckling inom behandlingen av inflammatoriska sjukdomar. Bolaget har utvecklat en plattformsteknologi som riktas mot allvarliga tillstånd inom kroniska inflammatoriska sjukdomar, samt främst ledskador.

SynAct Pharma är en läkemedelskoncern som bedriver forskning och utveckling inom behandlingen av inflammatoriska sjukdomar. Bolaget har utvecklat en plattformsteknologi som riktas mot allvarliga tillstånd inom kroniska inflammatoriska sjukdomar, samt främst ledskador.

SynAct Pharma AB, c/o Medicon Village AB, Scheelevägen 2,SE-223 81 Lund, Sweden.
Aroundio securitas direct

Press releases March 18, 2021 SynAct has initiated dosing in part 2 of the clinical Phase II study with AP1189 in Covid-19 infected patients UK version March 18, 2021 SynAct har inlett dosering i del 2 av den kliniska fas II-studien med AP1189 på Covid-19-infekterade patienter Den 1 juni 2016 kommer SynAct Pharma AB att presentera på Sedermeradagen i Göteborg. SynAct Pharma AB:s styrelseordförande Torbjørn Bjerke kommer att presentera bolaget kl. 12.50 – 13.20.

Spotlight Stock Market. Click to login.
När får man svar på deklarationen

SynAct Pharma komplett bolagsfakta & börsnyheter från Analysguiden. in accordance with the announcement made in a press release yesterday, successfully

2020-04-02 · Den 1 juni 2016 kommer SynAct Pharma AB att presentera på Sedermeradagen i Göteborg.

SynAct Pharma has initiated the Phase II clinical study with AP1189 in Nephrotic Syndrome Mon, Jun 29, 2020 07:49 CET. SynAct Pharma AB ("SynAct") today announced that the company has initiated a Phase II clinical study with the AP1189 compound in idiopathic membranous nephropathy patients with Nephrotic Syndrome.

Release Press release Synact Pharma 20200331 Covid19 - UK version. Se fullständigt pressmeddelande och andra nyheter från detta bolag på Cision News.

Translation - UK version of Swedish press release - published 08.00 AM. today - SynAct Pharma investigates the possibility of AP1189 as additional therapy in hospitalized patients with COVID-19 SynAct Pharma AB ("SynAct") today announced that dosing of the leading candidate drug AP1189 was successfully completed in the second cohort (100 mg dose level) in part 1 of the company's Phase IIa study in patients with Rheumatoid Arthritis (RA) with high disease activity. 2021-02-05 · Welcome to SynAct Pharma AB’s website. We use cookies to optimise your use of our website. A cookie is a text file that is stored on your computer. If you want further information about what a cookie is, what cookies we use, what the purpose of the cookie is or how you can block or delete cookies, please read “ SynAct Pharma AB ("SynAct" eller "Bolaget") meddelar härmed att Bolagets aktieägare TJ Biotech ApS (helägt av styrelseledamoten tillika CSO Thomas Jonassen) och Quantass ApS (ägt av verkställande direktören Jeppe Øvlesen och dennes hustru Ghita Øvlesen) har genomfört en bolagsrättslig omstrukturering varigenom respektive bolags innehav av aktier i SynAct har övergått genom fusion SynAct Pharma AB ("SynAct") today announces that the company's Board of Directors and management have agreed to subscribe for 100 percent of the Board of Directors and management's total holding of warrants of series TO 2 ("TO 2"). SynAct Pharma AB ("SynAct") today announced that the European Patent Office (EPO) issued an "Intention to grant" for SynAct's patent application covering the company's leading drug candidate AP1189 in methods of treating kidney diseases. SynAct Pharma AB ("SynAct"), a clinical stage biopharmaceutical company developing novel therapies of inflammatory diseases, Synact Pharma Press release 20201109.